Literature DB >> 27456357

Knockdown of USP39 induces cell cycle arrest and apoptosis in melanoma.

Yuan Zhao1,2,3,4, Bo Zhang5, Yu Lei1,2,6, Jingying Sun1,2,3, Yaohua Zhang7,8, Sen Yang1,2,3, Xuejun Zhang9,10,11,12.   

Abstract

The spliceosome machinery composed of multimeric protein complexes guides precursor messenger RNAs (mRNAs) (pre-mRNAs) splicing in eukaryotic cells. Spliceosome components have been shown to be downregulated in cancer and could be a promising molecular target for anticancer therapy. The ubiquitin-specific protease 39 (USP39) is essential for pre-mRNA splicing, and upregulated USP39 expression is noted in a variety of cancers. However, the role of USP39 in the development and progression of melanoma remains unclear. In the present study, USP39 expression was found to be increased in melanoma tissues compared with that in nevus tissues. USP39 silencing via lentivirus-mediated short hairpin RNA (shRNA) significantly suppressed melanoma cell proliferation, induced G0/G1 cell cycle phase arrest, and increased apoptosis in vitro. Moreover, USP39 knockdown suppressed melanoma tumor growth in a xenograft model. In addition, USP39 silencing was associated with the increased expressions of p21, p27, and Bax. Furthermore, the inhibition of USP39 expression decreased the phosphorylation of extracellular signal-regulated kinase (ERK)1/2, indicating that ERK signaling pathways might be involved in the regulation of melanoma cell proliferation by USP39. Our findings suggest that USP39 may play crucial roles in the development and pathogenesis of melanoma, and it may serve as a potential therapeutic target for melanoma.

Entities:  

Keywords:  Apoptosis; Cell cycle arrest; ERK; Melanoma; USP39

Mesh:

Substances:

Year:  2016        PMID: 27456357     DOI: 10.1007/s13277-016-5212-x

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  40 in total

Review 1.  CDK inhibitors: cell cycle regulators and beyond.

Authors:  Arnaud Besson; Steven F Dowdy; James M Roberts
Journal:  Dev Cell       Date:  2008-02       Impact factor: 12.270

Review 2.  Aberrant RNA splicing and its functional consequences in cancer cells.

Authors:  James D Fackenthal; Lucy A Godley
Journal:  Dis Model Mech       Date:  2008 Jul-Aug       Impact factor: 5.758

Review 3.  Advances in targeted therapy for unresectable melanoma: new drugs and combinations.

Authors:  Mengze Hao; Fengju Song; Xiaoling Du; Guowen Wang; Yun Yang; Kexin Chen; Jilong Yang
Journal:  Cancer Lett       Date:  2015-01-08       Impact factor: 8.679

4.  Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib.

Authors:  Jeffrey A Sosman; Kevin B Kim; Lynn Schuchter; Rene Gonzalez; Anna C Pavlick; Jeffrey S Weber; Grant A McArthur; Thomas E Hutson; Stergios J Moschos; Keith T Flaherty; Peter Hersey; Richard Kefford; Donald Lawrence; Igor Puzanov; Karl D Lewis; Ravi K Amaravadi; Bartosz Chmielowski; H Jeffrey Lawrence; Yu Shyr; Fei Ye; Jiang Li; Keith B Nolop; Richard J Lee; Andrew K Joe; Antoni Ribas
Journal:  N Engl J Med       Date:  2012-02-23       Impact factor: 91.245

Review 5.  Pre-mRNA splicing in cancer: the relevance in oncogenesis, treatment and drug resistance.

Authors:  Anna Wojtuszkiewicz; Yehuda G Assaraf; Marielle J P Maas; Gertjan J L Kaspers; Gerrit Jansen; Jacqueline Cloos
Journal:  Expert Opin Drug Metab Toxicol       Date:  2014-12-13       Impact factor: 4.481

Review 6.  The spliceosome as a target of novel antitumour drugs.

Authors:  Sophie Bonnal; Luisa Vigevani; Juan Valcárcel
Journal:  Nat Rev Drug Discov       Date:  2012-11       Impact factor: 84.694

7.  Usp39 is essential for mitotic spindle checkpoint integrity and controls mRNA-levels of aurora B.

Authors:  Renske J van Leuken; Mark P Luna-Vargas; Titia K Sixma; Rob M F Wolthuis; René H Medema
Journal:  Cell Cycle       Date:  2008-09-03       Impact factor: 4.534

8.  Zebrafish usp39 mutation leads to rb1 mRNA splicing defect and pituitary lineage expansion.

Authors:  Yesenia Ríos; Shlomo Melmed; Shuo Lin; Ning-Ai Liu
Journal:  PLoS Genet       Date:  2011-01-13       Impact factor: 5.917

Review 9.  Functional roles of protein splicing factors.

Authors:  Hsin-Chou Chen; Soo-Chen Cheng
Journal:  Biosci Rep       Date:  2012-08       Impact factor: 3.840

10.  Reduced USP39 expression inhibits malignant proliferation of medullary thyroid carcinoma in vitro.

Authors:  Yong An; Shuwen Yang; Kai Guo; Ben Ma; Yu Wang
Journal:  World J Surg Oncol       Date:  2015-08-25       Impact factor: 2.754

View more
  12 in total

Review 1.  More than a messenger: Alternative splicing as a therapeutic target.

Authors:  A J Black; J R Gamarra; J Giudice
Journal:  Biochim Biophys Acta Gene Regul Mech       Date:  2019-07-02       Impact factor: 4.490

Review 2.  Research Progress of DUB Enzyme in Hepatocellular Carcinoma.

Authors:  Jie Zhao; Jinhui Guo; Yanan Wang; Qiancheng Ma; Yu Shi; Feng Cheng; Qiliang Lu; Wen Fu; Guangxiong Ouyang; Ji Zhang; Qiuran Xu; Xiaoge Hu
Journal:  Front Oncol       Date:  2022-06-27       Impact factor: 5.738

3.  miR-133a, directly targeted USP39, suppresses cell proliferation and predicts prognosis of gastric cancer.

Authors:  Xiang Dong; Hailong Su; Feng Jiang; Haiyan Li; Guangwen Shi; Lijuan Fan
Journal:  Oncol Lett       Date:  2018-04-04       Impact factor: 2.967

4.  USP39 regulates the cell cycle, survival, and growth of human leukemia cells.

Authors:  Chunxia Liu; Xiaojian Yao; Ming Li; Yaming Xi; Li Zhao
Journal:  Biosci Rep       Date:  2019-04-05       Impact factor: 3.840

5.  RNA splicing factor USP39 promotes glioma progression by inducing TAZ mRNA maturation.

Authors:  Kaikai Ding; Jianxiong Ji; Xin Zhang; Bin Huang; Anjing Chen; Di Zhang; Xingang Li; Xinyu Wang; Jian Wang
Journal:  Oncogene       Date:  2019-07-22       Impact factor: 9.867

Review 6.  Identifying Novel Actionable Targets in Colon Cancer.

Authors:  Maria Grazia Cerrito; Emanuela Grassilli
Journal:  Biomedicines       Date:  2021-05-20

7.  USP8 is a Novel Therapeutic Target in Melanoma Through Regulating Receptor Tyrosine Kinase Levels.

Authors:  Baoxue Duan; Changying Wang; Zeng Liu; Xiaoyu Yang
Journal:  Cancer Manag Res       Date:  2021-05-24       Impact factor: 3.989

8.  Systems analysis identifies melanoma-enriched pro-oncogenic networks controlled by the RNA binding protein CELF1.

Authors:  Metehan Cifdaloz; Lisa Osterloh; Osvaldo Graña; Erica Riveiro-Falkenbach; Pilar Ximénez-Embún; Javier Muñoz; Cristina Tejedo; Tonantzin G Calvo; Panagiotis Karras; David Olmeda; Belén Miñana; Gonzalo Gómez-López; Estela Cañon; Eduardo Eyras; Haihong Guo; Ferdinand Kappes; Pablo L Ortiz-Romero; Jose L Rodríguez-Peralto; Diego Megías; Juan Valcárcel; María S Soengas
Journal:  Nat Commun       Date:  2017-12-21       Impact factor: 14.919

Review 9.  Delineating Crosstalk Mechanisms of the Ubiquitin Proteasome System That Regulate Apoptosis.

Authors:  Ishita Gupta; Kanika Singh; Nishant K Varshney; Sameena Khan
Journal:  Front Cell Dev Biol       Date:  2018-02-09

10.  Deubiquitinase USP39 and E3 ligase TRIM26 balance the level of ZEB1 ubiquitination and thereby determine the progression of hepatocellular carcinoma.

Authors:  Xiaomei Li; Jiahui Yuan; Conghua Song; Yongbin Lei; Jiajia Xu; Gongye Zhang; Weiwei Wang; Gang Song
Journal:  Cell Death Differ       Date:  2021-03-01       Impact factor: 15.828

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.